Genetesis, Inc. is a medical technology company focused on redefining the way myocardial ischemia and coronary artery disease are detected. Genetesis’ flagship product, The CardioFlux Magnetocardiograph, is an FDA cleared, non-invasive, functional biomagnetic imaging system that measures the natural magnetic fields produced by the electrical activity in the heart.
CardioFlux leverages Magnetocardiography (MCG), a 40+ year old science that has previously been constrained by technical feasibility and heavy investments. CardioFlux has overcome these barriers of the past, and its technical advancements are poised to be easily integrated into clinical workflows.
All CardioFlux scans are performed at rest, with absolutely no patient exposure to radiation or pharmaceuticals. As a 90-second scan, CardioFlux is less time-intensive and costly to patients, providers and payers facing inefficiencies with the current standard of chest pain triage.
In the prospective emergency department observation unit clinical study, 101 low-intermediate risk chest pain patients received a 90-second CardioFlux® scan. CardioFlux® identified different magnetic field maps for patients with and without myocardial ischemia diagnosed via the standard of care evaluation.
Below, the PI of the Pilot study, Dr. Margarita Pena, walks through cases from the clinical trial:
A 53-year-old woman presented to the Emergency Room with potential ACS. Her HEART score was a 3. Her negative CardioFlux scan would have allowed a faster, more accurate, and less invasive Emergency Room visit.
A 68-year-old man presented to the Emergency Room with potential ACS. He had a family history of CAD, hyperlipidemia, hypertension and diabetes. His HEART score was a 6. His positive CardioFlux scan would have allowed a faster, more accurate and less invasive Emergency Room visit.
Rhea Malhotra | Director, Product